サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451893

経口抗生物質市場レポート：クラス別、用途、薬剤由来、活性領域、薬剤タイプ、地域、2024～2032年

Oral Antibiotics Market Report by Class, Application (Community-acquired Respiratory Tract Infections, Urinary Tract Infections, Dental and Others), Drug Origin, Spectrum of Activity, Drug Type, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 146 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
経口抗生物質市場レポート：クラス別、用途、薬剤由来、活性領域、薬剤タイプ、地域、2024～2032年
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経口抗生物質の世界市場規模は2023年に204億140万米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて3.32%の成長率（CAGR）を示し、2032年までに276億1,220万米ドルに達すると予測しています。感染症の蔓延、高齢者人口の増加、薬剤耐性菌に対する効果的な治療に対する需要の高まり、個別化医療とゲノミクスの動向の高まりなどが、市場を牽引する主要要因となっています。

経口抗生物質は、主に細菌の増殖を抑制したり、体内から細菌を除去するために処方される医薬品です。通常、口から服用し、幅広い医療用途で利用されています。経口抗生物質によって治療される感染症の種類は様々で、皮膚、耳、喉、尿路感染症などの一般的な疾患から、ある種の肺炎のような複雑な疾患まで含まれます。これらの抗生物質は異なるクラスに分類され、それぞれ作用機序が異なります。よく処方されるクラスには、ペニシリン系、フルオロキノロン系、テトラサイクリン系、マクロライド系などがあります。それぞれのクラスは、異なるタイプの細菌を標的とし、特定の細菌感染症により効果的です。例えば、ペニシリン系は溶連菌感染症に広く使用され、フルオロキノロン系は特定のグラム陰性菌に対抗するために選択されます。その結果、経口抗生物質は現代医療の重要な要素であり、多くの細菌感染症の治療を成功させるために医療専門家によって広く処方されています。

経口抗生物質の市場動向：

感染症の有病率の増加と、これらの症状に対する利用可能な治療オプションに関する一般市民の意識の高まりが、市場の成長を支える主要要因となっています。さらに、このような感染症を発症しやすい高齢者人口の拡大も、市場の成長を後押しする主要要因です。さらに、抗生物質の普及を促し、抗生物質耐性の出現を遅らせ、これらの薬剤の効果を長持ちさせることを目的とした抗生物質スチュワードシップ・プログラムが増加しています。これに伴い、抗生物質耐性の問題が深刻化しているため、研究者や製薬会社は既存の抗生物質クラスを変更し、多剤耐性菌に対応できる新しい抗生物質を開発せざるを得なくなり、製品採用率が加速しています。さらに、大手製薬会社や研究機関は、細菌の耐性パターンを予測し、薬剤と細菌の相互作用を理解し、新規抗生物質の発見を迅速化するために、創薬プロセスにおいて人工知能（AI）や機械学習（ML）を活用しています。これに伴い、個別化医療とゲノミクスの台頭が、治療効果を高め副作用を最小限に抑えるために遺伝的体質などの要因を考慮して個々の患者に合わせた抗生物質治療を行うことを含み、市場の成長を促進しています。薬剤耐性菌に対する効果的な治療に対する需要の高まり、医療インフラの改善、新規経口抗生物質の継続的な発売、研究開発（R&D）活動への多額の投資などのその他の要因も、今後数年間の市場成長を促進すると予想されます。

本レポートで扱う主要質問

  • 世界の経口抗生物質市場はこれまでどのように推移してきたか？
  • 世界の経口抗生物質市場における促進要因、抑制要因、機会は何か？
  • それぞれの促進要因、抑制要因、機会が世界の経口抗生物質市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的な経口抗生物質市場はどの国か？
  • クラス別の市場内訳は？
  • 経口抗生物質市場で最も魅力的なクラスは？
  • 用途別の市場内訳は？
  • 経口抗生物質市場で最も魅力的な用途は？
  • 薬剤由来に基づく市場内訳は？
  • 経口抗生物質市場で最も魅力的な薬剤由来は？
  • 活性領域に基づく市場内訳は？
  • 経口抗生物質市場で最も魅力的な活性領域は？
  • 薬剤タイプ別の市場内訳は？
  • 経口抗生物質市場で最も魅力的な薬剤タイプはどれですか？
  • 世界の経口抗生物質市場の競争構造は？
  • 世界の経口抗生物質市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 経口抗生物質の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：クラス別

  • βラクタム薬とβラクタマーゼ阻害薬
    • 市場動向
    • 主要セグメント
      • ペニシリン
      • セファロスポリン
      • その他
    • 市場予測
  • キノロン
  • マクロライド
  • その他

第7章 市場内訳：用途別

  • 市中呼吸器感染症（CARTI）
    • 市場動向
    • 主要セグメント
      • 上気道感染症（URTI）
      • 下部呼吸器管感染症（LRTI）
    • 市場予測
  • 尿路感染症（UTI）
  • 歯科
    • 市場動向
    • 主要セグメント
      • コンビネーション治療
      • 単剤治療
    • 市場予測
  • その他

第8章 市場内訳：薬剤由来別

  • 天然由来
  • 半合成
  • 合成

第9章 市場内訳：活性領域別

  • 広域抗生物質
  • 狭域抗生物質

第10章 市場内訳：薬剤タイプ別

  • ブランド
  • ジェネリック

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bayer AG
    • Cipla Inc
    • Gilead Sciences Inc
    • Janssen Inc.（Johnson & Johnson Services, Inc）
    • Pfizer Inc.
    • Roche Holding AG
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Oral Antibiotics Market: Major Drivers and Challenges
  • Figure 2: Global: Oral Antibiotics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Oral Antibiotics Market: Breakup by Class (in %), 2023
  • Figure 5: Global: Oral Antibiotics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Oral Antibiotics Market: Breakup by Drug Origin (in %), 2023
  • Figure 7: Global: Oral Antibiotics Market: Breakup by Spectrum of Activity (in %), 2023
  • Figure 8: Global: Oral Antibiotics Market: Breakup by Drug Type (in %), 2023
  • Figure 9: Global: Oral Antibiotics Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Oral Antibiotics (Beta Lactam and Beta Lactamase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Oral Antibiotics (Beta Lactam and Beta Lactamase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Oral Antibiotics (Quinolone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Oral Antibiotics (Quinolone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Oral Antibiotics (Macrolide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Oral Antibiotics (Macrolide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Oral Antibiotics (Other Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Oral Antibiotics (Other Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Oral Antibiotics (Community-acquired Respiratory Tract Infections (CARTIs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Oral Antibiotics (Community-acquired Respiratory Tract Infections (CARTIs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Oral Antibiotics (Urinary Tract Infections (UTIs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Oral Antibiotics (Urinary Tract Infections (UTIs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Oral Antibiotics (Dental) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Oral Antibiotics (Dental) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Oral Antibiotics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Oral Antibiotics (Other Applications) Market Forecast: Sales Value (in Million US$), 2018-2023
  • Figure 26: Global: Oral Antibiotics (Natural) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Oral Antibiotics (Natural) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Oral Antibiotics (Semisynthetic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Oral Antibiotics (Semisynthetic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Oral Antibiotics (Synthetic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Oral Antibiotics (Synthetic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Oral Antibiotics (Broad-spectrum Antibiotic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Oral Antibiotics (Broad-spectrum Antibiotic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Oral Antibiotics (Narrow Spectrum Antibiotic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Oral Antibiotics (Narrow Spectrum Antibiotic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Oral Antibiotics (Branded) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Oral Antibiotics (Branded) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Oral Antibiotics (Generics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Oral Antibiotics (Generics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Oral Antibiotics Market: Sales Value (in Million US$),2018 & 2023
  • Figure 41: North America: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Oral Antibiotics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Oral Antibiotics Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Oral Antibiotics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Oral Antibiotics Industry: Drivers, Restraints, and Opportunities
  • Figure 90: Global: Oral Antibiotics Industry: Value Chain Analysis
  • Figure 91: Global: Oral Antibiotics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oral Antibiotics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Oral Antibiotics Market Forecast: Breakup by Class (in Million US$), 2024-2032
  • Table 3: Global: Oral Antibiotics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Oral Antibiotics Market Forecast: Breakup by Drug Origin (in Million US$), 2024-2032
  • Table 5: Global: Oral Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million US$), 2024-2032
  • Table 6: Global: Oral Antibiotics Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 7: Global: Oral Antibiotics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Oral Antibiotics Market: Competitive Structure
  • Table 9: Global: Oral Antibiotics Market: Key Players
目次
Product Code: SR112024A8355

The global oral antibiotics market size reached US$ 20,401.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 27,612.2 Million by 2032, exhibiting a growth rate (CAGR) of 3.32% during 2024-2032. The increasing prevalence of infectious diseases, expanding geriatric population, escalating demand for effective treatments against drug-resistant bacteria, and the growing trend of personalized medicine and genomics represent some of the key factors driving the market.

Oral antibiotics are pharmaceutical agents primarily prescribed to inhibit bacterial growth or eliminate bacteria from the body. They are usually taken by mouth and are utilized across a wide range of medical applications. The types of infections treated by oral antibiotics vary and include common ailments such as skin, ear, throat, and urinary tract infections and more complex conditions like certain types of pneumonia. These antibiotics are categorized into different classes, each with a distinct mechanism of action. Some commonly prescribed classes include penicillins, fluoroquinolones, tetracyclines, and macrolides. Each class targets different types of bacteria and is more effective for specific bacterial infections. For instance, penicillins are widely used for streptococcal infections, while fluoroquinolones may be chosen to combat certain gram-negative bacteria. As a result, oral antibiotics are a key element of modern healthcare and are widely prescribed by healthcare professionals to enable the successful treatment of numerous bacterial infections.

Oral Antibiotics Market Trends:

The increasing prevalence of infectious diseases and the rising public awareness about the available treatment options for these conditions represent the primary factors supporting market growth. Moreover, the expanding geriatric population that is more susceptible to developing such infections is another major factor fueling the market growth. In addition, there has been a rise in antibiotic stewardship programs aimed at encouraging the widespread use of antibiotics, slowing down the emergence of antibiotic resistance, and ensuring the prolonged effectiveness of these drugs. Along with this, the growing issue of antibiotic resistance has compelled researchers and pharmaceutical companies to modify existing classes and develop new antibiotics capable of treating multi-drug resistant bacteria, thereby accelerating the product adoption rate. Furthermore, the leading pharmaceutical companies and research institutes are leveraging artificial intelligence (AI) and machine learning (ML) in the drug discovery process to predict bacterial resistance patterns, understand drug-bacteria interactions, and expedite the discovery of novel antibiotics. In line with this, the emergence of personalized medicine and genomics, which involves tailoring antibiotic treatment to individual patients by considering factors such as their genetic makeup to enhance treatment effectiveness and minimize side effects, has catalyzed market growth. Other factors, including escalating demand for effective treatments against drug-resistant bacteria, improving healthcare infrastructure, the continual launch of novel oral antibiotics, and heavy investments in research and development (R&D) activities, are also anticipated to propel the market growth in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global oral antibiotics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on the class, application, drug origin, spectrum of activity, and drug type.

Class Insights:

Beta Lactam and Beta Lactamase Inhibitors

Penicillin

Cephalosporin

Others

Quinolone

Macrolide

Others

The report has provided a detailed breakup and analysis of the oral antibiotics market based on the class. This includes beta lactam and beta lactamase inhibitors (penicillin, cephalosporin, and others), quinolone, macrolide, and others. According to the report, beta lactam and beta lactamase inhibitors represented the largest segment.

Application Insights:

Community-acquired Respiratory Tract Infections (CARTIs)

Upper Respiratory Tract Infections (URTI)

Lower Respiratory Tract Infections (LRTIs)

Urinary Tract Infections (UTIs)

Dental

Combination

Monotherapies

Others

A detailed breakup and analysis of the oral antibiotics market based on the application has also been provided in the report. This includes community-acquired respiratory tract infections (upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs)), urinary tract infections (UTIs), dental (combination and monotherapies), and others. According to the report, urinary tract infections (UTIs) accounted for the largest market share.

Drug Origin Insights:

Natural

Semisynthetic

Synthetic

The report has provided a detailed breakup and analysis of the oral antibiotics market based on the drug origin. This includes natural, semisynthetic, and synthetic. According to the report, synthetic represented the largest segment.

Spectrum of Activity Insights:

Broad-spectrum Antibiotic

Narrow Spectrum Antibiotic

A detailed breakup and analysis of the oral antibiotics market based on the spectrum of activity has also been provided in the report. This includes broad-spectrum antibiotic and narrow spectrum antibiotic.

Drug Type Insights:

Branded

Generics

The report has provided a detailed breakup and analysis of the oral antibiotics market based on the drug type. This includes branded and generics.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia-Pacific was the largest market for oral antibiotics. Some of the factors driving the Asia-Pacific oral antibiotics market included its aging population, growing burden of infectious diseases, high healthcare expenditure, the presence of various key players, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global oral antibiotics market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bayer AG, Cipla Inc., Gilead Sciences Inc., Janssen Inc. (Johnson & Johnson Services, Inc.), Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global oral antibiotics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global oral antibiotics market?
  • What is the impact of each driver, restraint, and opportunity on the global oral antibiotics market?
  • What are the key regional markets?
  • Which countries represent the most attractive oral antibiotics market?
  • What is the breakup of the market based on the class?
  • Which is the most attractive class in the oral antibiotics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the oral antibiotics market?
  • What is the breakup of the market based on the drug origin?
  • Which is the most attractive drug origin in the oral antibiotics market?
  • What is the breakup of the market based on the spectrum of activity?
  • Which is the most attractive spectrum of activity in the oral antibiotics market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the oral antibiotics market?
  • What is the competitive structure of the global oral antibiotics market?
  • Who are the key players/companies in the global oral antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oral Antibiotics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Class

  • 6.1 Beta Lactam and Beta Lactamase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Penicillin
      • 6.1.2.2 Cephalosporin
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Quinolone
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Macrolide
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Community-acquired Respiratory Tract Infections (CARTIs)
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Upper Respiratory Tract Infections (URTI)
      • 7.1.2.2 Lower Respiratory Tract Infections (LRTIs)
    • 7.1.3 Market Forecast
  • 7.2 Urinary Tract Infections (UTIs)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dental
    • 7.3.1 Market Trends
    • 7.3.2 Key Segments
      • 7.3.2.1 Combination
      • 7.3.2.2 Monotherapies
    • 7.3.3 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Origin

  • 8.1 Natural
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Semisynthetic
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Synthetic
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Spectrum of Activity

  • 9.1 Broad-spectrum Antibiotic
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Narrow Spectrum Antibiotic
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Drug Type

  • 10.1 Branded
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Generics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Bayer AG
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Cipla Inc
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Gilead Sciences Inc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Janssen Inc. (Johnson & Johnson Services, Inc)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
    • 16.3.5 Pfizer Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Roche Holding AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Sun Pharmaceutical Industries Ltd
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Teva Pharmaceutical Industries Ltd.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.